Table 1. Impact of triglyceride lowering genes on CAD and T2DM.
| Gene | Number of variants | Triglyceride | HDL cholesterol | LDL cholesterol | CAD Odds ratio | T2DM Odds ratio |
|---|---|---|---|---|---|---|
| LPL | 7 | −0.138 ± 0.002 (<1.0 × 10−237) |
0.939 ± 0.011 (<1.0 × 10−237) |
0.025 ± 0.012 (0.03) |
0.66 | 0.8 |
| ANGPTL4 | 1 | −0.273 ± 0.01 (4.2 × 10−175) |
0.891 ± 0.035 (4.8 × 10−146) |
−0.014 ± 0.036 (0.7) |
0.6 | 0.67 |
| APOA5 | 7 | −0.227 ± 0.002 (<1.0 × 10−237) |
0.453 ± 0.009 (<1.0 × 10−237) |
−0.145 ± 0.009 (8.4 × 10−59) |
0.76 | 0.88 |
| APOC3 | 3 | −1.069 ± 0.032 (3.2 × 10−237) |
0.695 ± 0.03 (9.0 × 10−120) |
−0.106 ± 0.03 (4.7 × 10−4) |
0.85 | 1.07 |
| ANGPTL3 | 1 | −0.077 ± 0.003 (6.1 × 10−170) |
−0.136 ± 0.035 (1.2 × 10−4) |
−0.588 ± 0.037 (4.8 × 10−58) |
0.89 | 1.18 |
| ANGPTL8 | 1 | −0.353 ± 0.051 (2.8 × 10−12) |
1.221 ± 0.141 (5.0 × 10−18) |
−0.167 ± 0.146 (0.25) |
0.74 | 1.58 |
Value are expressed as effect size ± S.E. (p-value). LPL = lipoprotein lipase; ANGPTL4 = angiopoietin-like 4; APOA5 = apolipoprotein A5; APOC3 = apolipoprotein C3; ANGPTL3 = Angiopoietin-like 3; ANGPTL8 = Angiopoietin-like 8; CAD = coronary artery disease; T2DM = type 2 diabetes mellitus